Pressemelding -

PRESS RELEASE: Calanus As invests in a new production facility

The decision has been triggered by the Government's decision to open for commercial harvesting of Calanus finmarchicus and the increasing demand for the company's products.

Tromsø, Norway, June 4, 2019.

Calanus AS is a Norwegian biomarine company pioneering harvesting and utilization of the copepod Calanus finmarchicus. The company has developed the entire value chain for sustainable harvesting and biorefining of the hitherto unused resource C. finmarchicus, which is Norway's largest renewable and harvestable marine resource. Calanus AS manufactures unique health and nutrition products that are for sale or under launch in several countries. Based on the Government's decision to open for commercial harvesting of C. finmarchicus, and increasing demand for the company's products, Calanus AS has now decided to build the first full-scale industrial pilot plant for biorefining of C. finmarchicus. The plant will be located above the Arctic circle, in Sortland in northern Norway.

CEO Gunnar Rørstad in Calanus AS states: “We are pleased that the Ministry of Trade, Industry and Fisheries has decided to open for commercial harvesting of Calanus finmarchicus. Calanus AS has developed extensive knowledge on the harvesting of the resource and its products - as well as the market opportunities for this exciting raw material. The market potential for our unique health and nutrition products has been confirmed, both through strong customer growth in Norway and considerable international interest. To be able to serve existing and future customers, it is absolutely necessary to increase our production capacity.”.

The factory project has a total investment budget of EUR 18 million, of which EUR 7 million is to be financed with equity.

The company's main product is Calanus® Oil, an ecologically responsible and sustainable source of omega-3 fatty acids for humans. Calanus® Oil has a unique composition and has shown beneficial properties such as improved insulin sensitivity, reduction of intra-abdominal obesity and strong anti-inflammatory effects. Calanus As is now working on further development of clinical documentation in humans in several countries with an aim to apply for approval of health claims in accordance with EU and other Authorities' regulation. The company also works with functional ingredients aimed at both human and animal applications, including the global aquaculture industry.

For more information, contact CEO Gunnar Rørstad on phone +47 913 65 942 or e-mail: gunnar.rorstad@calanus.no, or visit the Calanus website www.calanus.com. 

Related links

Emner

Calanus As is a biomarine company pioneering harvesting and utilization of the crustacean Calanus finmarchicus, and is well positioned to play a key role in industrialization of the entire value chain for through its intellectual property rights. Calanus As develops functional health- and nutrition ingredients for humans and animals exclusively from this valuable raw material. The Company’s main product is Calanus® Oil, an ecologically sustainable source of omega-3 fatty acids for humans. Calanus® Oil has unique composition and has shown benefits like improved insulin sensitivity, reduced deposition of intra-abdominal fat and powerful anti-inflammatory effects.

Kontakter

Relatert media

Relatert innhold

  • PRESS RELEASE: Norway opens for commercial harvesting of zooplankton

    Tromsø, Norway, April 1st 2019.
    The Norwegian Government has decided to open for commercial harvesting of Calanus finmarchicus, the small copepod that constitutes the largest renewable and harvestable resource in the Norwegian sea.
    Based on a precautionary approach, the quota has initially been set at 254 000 tons per year, which is significantly lower than the potential sustainable yield.<

  • Calanus® Oil approved by Health Canada

    Health Canada´s Natural and Non-prescription Health Products Directorate (NNHPD) has approved Calanus® Oil as a Natural Health Product.

  • PRESS RELEASE: First Review Article on Health Effects of Wax Ester Omega-3s

    A recent review article by Schots et al., published in Frontiers in Pharmacology, investigates how the different constituents of Calanus® Oil can contribute to the prevention of obesity-induced low-grade inflammation and the associated metabolic disturbances. Calanus® Oil is a natural oil derived from the 1-year copepod Calanus finmarchicus. In addition to having the unique wax ester form, Calanus

  • Norway files application to include Calanus Oil in Codex Alimentarius

    Norwegian Authorities, represented by the Norwegian Food Safety Authority, have submitted an application to the Codex Alimentarius Commission to include calanus oil in the Codex Standard (CODEX STAN 329-2017). Codex Alimentarius is a joint initiative from The Food and Agriculture Organization and World Health Organization, both organizations from the United Nations.
    Oil from Calanus finmarchicu

  • PRESS RELEASE: A new study shows that Calanus® Oil intake antagonizes negative changes in gut microbiota due to obesity

    A new preclinical study conducted by a research team from Uit- The Arctic University of Norway, shows that Calanus® Oil supplementation in obese mice prevents negative changes in microbiota. This has led to new theories about the mechanisms of action of Calanus® Oil.
    Current evidence suggests that obesity and its comorbidities are intrinsically linked with unfavorable changes in the intestinal

  • Calanus AS certified by Friend of the Sea®

    Tromsø, Norway, December 11, 2020

    Friend of the Sea®, one of the leading global certification standards for products and services that respect and protect the marine environment, has certified Calanus AS for harvesting of the zooplankton Calanus finmarchicus and the products derived from this huge marine resource. Calanus AS can now display the Friend of the Sea® eco-friendly label on their

Fyll ut e-postadressen din for å følge Zooca (Calanus AS)

Når du velger å følge et nyhetsrom og opprette en brukerkonto vil dine personopplysninger bli benyttet av oss og av nyhetsrommets eier for å sende deg nyheter og oppdateringer i henhold til dine varslingsinnstillinger.

For mer informasjon, les vår Personvernspolicy, som gjelder for vår bruk av dine personopplysninger, og vår Personvernspolicy for Contacts, som gjelder for nyhetsrommets eiers bruk av dine personopplysninger.

Vær oppmerksom på at våre Brukervilkår gjelder for all bruk av våre tjenester.

Du kan trekke tilbake ditt samtykke når som helst ved å melde deg ut eller slette din konto.
Sjekk innboksen din

E-post sendt til __email__. Klikk på lenken i e-posten for å følge Zooca (Calanus AS) .

Ok